Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

British Journal of Haematology

Volumn 150, Issue 2, 2010, Pages 200-208

  Romaguera, Jorge E ^a   Fayad, Luis E ^a   Feng, Lei ^a   Hartig, Kimberly ^a   Weaver, Pamela ^a   Rodriguez, Maria Alma ^a   Hagemeister, Fredrick B ^a   Pro, Barbara ^a   McLaughlin, Peter ^a   Younes, Anas ^a   Samaniego, Felipe ^a   Goy, Andre ^b   Cabanillas, Fernando ^a,c   Kantarjian, Hagop ^d   Kwak, Larry ^a   Wang, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c Auxilio Mutuo Hospital   (Puerto Rico)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

hyper CVAD; mantle cell lymphoma; methotrexate cytarabine; rituximab; survival

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG MEGADOSE; FOLLOW UP; GROUPS BY AGE; HUMAN; IMMUNOTHERAPY; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SCORING SYSTEM; THERAPY EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE;

AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIDEMIOLOGIC METHODS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; METHOTREXATE; MIDDLE AGED; TREATMENT OUTCOME; VINCRISTINE;

EID: 77954334194     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08228.x     Document Type: Article

References (32)

1. Andersen, N.S., Pedersen, L.B., Laurel, A., Elonen, E., Kolstad, A., Boesen, A.M., Pedersen, L.M., Lauritzsen, G.F., Ekanger, R., Nilsson-Ehle, H., Nordström, M., Fredén, S., Jerkeman, M., Eriksson, M., Väärt, J., Malmer, B. Geisler, C.H. (2009) Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. Journal of Clinical Oncology, 27, 4365 4370.
2. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report on an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
3. Cortes, J., O'Brien, S.M., Pierce, S., Keating, M.J., Freireich, E.J. Kantarjian, H.M. (1995) The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood, 15, 2091 2097.
4. De Guibert, S., Jaccard, A., Bernard, M., Turlure, P., Bordessoule, D. Lamy, T. (2006) Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica, 91, 425 426.
5. Delarue, R., Haioun, C. Ribrag, V. (2008) RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA. Blood (ASH Annual Meeting Abstracts 112, Abstract 581.
6. Determann, O., Hoster, E., Ott, G., Wolfram, B.H., Loddenkemper, C., Hansmann, L.M., Barth, T.E., Unterhalt, M., Hiddemann, W., Dreyling, M. Klapper, W. (2008) European Mantle Cell Lymphoma Network and the German Low Grade Lymphoma Study Group Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood, 111, 2385 2387.
7. Dreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C., Schmits, R., Metzner, B., Truemper, L., Reiser, M., Steinhauer, H., Boiron, J.M., Boogaerts, M.A., Aldaoud, A., Silingardi, V., Kluin-Nelemans, H.C., Hasford, J., Parwaresch, R., Unterhalt, M. Hiddemann, W. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood, 105, 2677 2684.
8. Epner, E.M., Unger, J., Miller, T., Rimzsa, L., Spier, C., Leblanc, M. Fisher, R. (2007) A multi center trial of hypercvad+rituxan in patients with newly diagnosed mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts 110, Abstract 387.
9. Evens, A.M., Winter, J.N., Hou, N., Nelson, B.P., Rademaker, A., Patton, D., Singhal, S., Frankfurt, O., Tallman, M.S., Rosen, S.T., Mehta, J. Gordon, L.I. (2008) A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. British Journal of Haematology, 140, 385 393.
10. Fayad, L.E., Thomas, D.A. Romaguera, J.E. (2007) Update of the M.D Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clinical Lymphoma and Myeloma, 8, S57 S62.
11. Garcia, M., Romaguera, J.E., Inamdar, K.V., Rassidakis, G.Z. Medeiros, L.J. (2009) Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer, 115, 1041 1048.
12. Geisler, C.H., Kolstad, A., Laurell, A., Andersen, N.S., Pedersen, L.B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A.M., Kuittinen, O., Lauritzsen, G.F., Nilsson-Ehle, H., Ralfkiaer, E., Akerman, M., Ehinger, M., Sundström, C., Langholm, R., Delabie, J., Karjalainen- Lindsberg, M.L., Brown, P., Elonen, E. Nordic Lymphoma Group. (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 112, 2687 2693.
13. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. Bloomfield, C.D. (2000) The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Arlie House, Virginia, November 1997. Histopathology, 36, 69 86.
14. Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wörmann, B., Trümper, L., Pfreundschuh, M., Einsele, H., Hiddemann, W., Unterhalt, M. Dreyling, M. (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. Journal of Clinical Oncology, 27, 511 518.
15. Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H.C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., Peter, N., Jung, W., Wörmann, B., Ludwig, W.D., Dührsen, U., Eimermacher, H., Wandt, H., Hasford, J., Hiddemann, W., Unterhalt, M. German Low Grade Lymphoma Study Group (GLSG) European Mantle Cell Lymphoma Network 2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood, 111, 558 565.
16. Kahl, B.S., Longo, W.L., Eickhoff, J.C., Zehnder, J., Jones, C., Blank, J., McFarland, T., Bottner, W., Rezazedeh, H., Werndli, J., Bailey, H.H. Wisconsin Oncology Network. (2006) Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Annals of Oncology, 17, 1418 1423.
17. Kaplan, E.L. Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457 481.
18. Lefrère, F., Delmer, A., Levy, V., Delarus, R., Varet, B. Hermine, O. (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica, 89, 1275 1276.
19. Magni, M., Di Nicola, C., Carlo-Stella, P., Matteucci, P., Devizzi, L., Tarella, C., Benedetti, F., Martelli, M., Patti, C., Parvis, G., Rambaldi, A., Barbui, T. Gianni, A.M. (2008) High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplantation, 43, 509 511.
20. Majlis, A., Pugh, W.C., Rodriguez, M.A., Benedict, W.F. Cabanillas, F. (1997) Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. Journal of Oncology, 15, 1664 1671.
21. Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R.R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., Diliberto, M., Melnick, A., Knowles, D.M., Chen-Kiang, S., Coleman, M. Leonard, J.P. (2009) Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of Clinical Oncology, 10, 1209 1213.
22. Peto, R. Peto, J. (1972) Asymptotically efficient rank invariant test procedures. Journal of Statistical Society, 35, 185 207.
23. Pott, C., Schrader, C., Gesk, S., Harder, L., Tiemann, M., Raff, T., Brüggemann, M., Ritgen, M., Gahn, B., Unterhalt, M., Dreyling, M., Hiddemann, W., Siebert, R., Dreger, P. Kneba, M. (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood, 107, 2271 2278.
24. Ritchie, D.S., Seymour, J.F., Grigg, A.P., Roberts, A.W., Hoyt, R., Thompson, S., Szer, J. Prince, H.M. (2007) The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Annals of Hematology, 86, 101 105.
25. Romaguera, J.E., Fayad, L.E., Rodriguez, M.A., Broglio, K.R., Hagemeister, F.B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., Sarris, A.H., Dang, N.H., Wang, M., Beasley, V., Medeiros, L.J., Katz, R.L., Gagneja, H., Samuels, B.I., Smith, T.L. Cabanillas, F.F. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose Methotrexate and Cytarabine. Journal of Clinical Oncology, 23, 7013 7023.
26. Tam, C.S., Bassett, R., Ledesma, C., Korbling, M., Alousi, A., Hosing, C., Kebraei, P., Harrell, R., Rondon, G., Giralt, S.A., Anderlini, P., Popat, U., Pro, B., Samuels, B., Hagemeister, F., Medeiros, L.J., Champlin, R.E. Khouri, I.F. (2009) Mature results of the M D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood, 113, 4144 4152.
27. The International non-Hodgkin's Lymphoma Prognostic Factors Project 1993) Predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987 994.
28. Thieblemont, C., Antal, D., Lacotte-Thierry, L., Delwail, V., Espinouse, D., Michallet, A.S., Traulle, C., Bouafia-Sauvy, F., Giraud, C., Salles, G., Guilhot, F. Coiffier, B. (2005) Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer, 104, 1434 1441.
29. Vandenberghe, E., Ruiz de Elvire, C., Loberiza, F.R., Conde, E., López-Guillermo, A., Gisselbrecht, C., Guilhot F,., Vose, J.M., van Biesen, K., Rizzo, J.D., Weisenburger, D.D., Isaacson, P., Horowitz, M.M., Goldstone, A.H., Lazarus, H.M. Schmitz, N. (2003) Outcome of autologous transplantation for mantle cell lymphoma: a study by the european blood and bone marrow transplant and autologous blood and marrow transplant registries. British Journal of Haematology, 120, 793 800.
30. Van't Veer, M.B., De Jong, D., Mackenzie, M., Kluin-Nelemans, H.C., Van Oers, M.H., Zijlstra, J., Hagenbeek, A. Van Putten, W.L. (2008) High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. British Journal of Haematology, 144, 524 530.
31. Vigouroux, S., Gaillard, F., Moreau, P., Harousseau, J.L. Milpied, N. (2005) High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica, 90, 1580 1582.
32. Vose, J., Loberiza, F., Bierman, P., Bociek, G. Armitage, J. (2006) Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 24, 7511.